Full Press Release Details
NeuroSense Granted South Korean Patent Covering
PrimeC Composition for ALS
CAMBRIDGE, Mass., June 11, 2026 /PRNewswire/
-- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"
or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative
diseases, today announced that the Korean Intellectual Property Office (KIPO) has issued Korean Patent Number 10-2969898 covering the
composition of PrimeC, the Company's lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS).
The granted patent claims cover key aspects of
PrimeC, including its proprietary tablet formulation, manufacturing process, pharmacokinetic characteristics, and pharmaceutical use for
the treatment of ALS.
The patent is expected to provide patent protection
for such aspects of PrimeC in South Korea through 2042.
"This patent grant further strengthens our
growing global intellectual property estate surrounding PrimeC," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "South
Korea is an important pharmaceutical market, and this milestone reflects the continued recognition of the novelty and proprietary nature
of PrimeC as we advance toward Phase 3 development."
The South Korean patent grant follows patent grants
received in other major jurisdictions, further expanding NeuroSense's global intellectual property portfolio and supporting the
long-term development and commercialization strategy for PrimeC.
PrimeC is a novel oral therapy designed to simultaneously
target multiple biological mechanisms associated with ALS progression, including neuroinflammation, oxidative stress and dysregulated
NeuroSense previously reported compelling results
from its Phase 2b PARADIGM study, including meaningful slowing of disease progression, significant biological activity across multiple
ALS-related biomarkers, including microRNAs, and long-term data demonstrating a meaningful survival benefit. The Company has received
clearance from the U.S. Food and Drug Administration (FDA) to initiate its pivotal Phase 3 PARAGON study in ALS.
NeuroSense Therapeutics is a late-clinical stage
biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS)
and Alzheimer's disease. The Company's lead product candidate, PrimeC, is a novel oral therapy designed to target multiple
key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.
NeuroSense has generated compelling clinical data
from its Phase 2b PARADIGM study in ALS, demonstrating meaningful slowing of disease progression. The Company also reported significant
biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC's multi-target mechanism
of action. Notably, long-term follow-up data indicated a meaningful survival benefit, representing a potentially important advancement
in the treatment of ALS.
NeuroSense has received clearance from the U.S.
Food and Drug Administration (FDA) to initiate a pivotal Phase 3 clinical trial (PARAGON) in ALS, which is expected to enroll approximately
300 participants, primarily in the United States.
For additional information, we invite you to visit
Information that may be important to investors may be routinely posted on our website and these social media channels.
PrimeC, NeuroSense's lead drug candidate, is a
novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib.
PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation,
iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.
Amyotrophic lateral sclerosis ("ALS")
is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than
5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with
ALS is expected to grow by 24% by 2040 in the U.S. and EU.
Forward-Looking Statements
This press release contains "forward-looking statements"
that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words
such as "anticipate," "believe," "contemplate," "could," "estimate," "expect,"
"intend," "seek," "may," "might," "plan," "potential," "predict,"
"project," "target," "aim," "should," "will" "would," or the negative of these
words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based
on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to
predict. Further, certain forward-looking statements, including statements regarding the benefits of the Korean patent, development, regulatory
progress and potential commercialization of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The
future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the
forward looking statements. These risks include the uncertainty regarding the benefits of the Korean patent; outcomes and the timing of
current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study
will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's
filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future.
More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the
Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense's subsequent filings with
the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update
such information except as required under applicable law.
For further information: Email: info@neurosense-tx.com,
Tel: +972 (0)9 799 6183